XML 11 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Net revenue    
Total net revenue $ 255,737 $ 145,820
Cost and operating expenses    
Technology research and development 33,391 27,067
Research and development 35,874 24,340
Selling, general and administrative 154,627 79,564
Total cost and operating expenses 324,426 199,094
Loss from operations (68,689) (53,274)
Interest income 1,813 1,031
Interest expense (18,003) (13,238)
Other (expense) income, net (27,455) 749
Loss before benefit from (provision for) income taxes (112,334) (64,732)
Benefit from (provision for) income taxes 46,180 (11)
Losses from equity method investments (1,883) 0
Net Loss (68,037) (64,743)
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares 0 (27,807)
Cumulative undeclared dividends on Series C preferred shares 0 (506)
Net loss attributable to common shareholders, basic (68,037) (93,056)
Net loss attributable to common shareholders, diluted $ (68,037) $ (93,056)
Net loss per share attributable to common shareholders, basic $ (0.4) $ (1.47)
Net loss per share attributable to common shareholders, diluted $ (0.4) $ (1.47)
Weighted-average shares outstanding used to compute net loss per share, basic 170,506 63,430
Weighted-average shares outstanding used to compute net loss per share, diluted 170,506 63,430
Comprehensive Loss, net of tax    
Net loss $ (68,037) $ (64,743)
Foreign currency translation adjustment 4,598 (56)
Comprehensive loss (63,439) (64,799)
Genomics [Member]    
Net revenue    
Total net revenue 193,804 102,569
Cost and operating expenses    
Cost of revenues 84,783 52,835
Data and services [Member]    
Net revenue    
Total net revenue 61,933 43,251
Cost and operating expenses    
Cost of revenues $ 15,751 $ 15,288